Bischloroanthrabenzoxocinone – 2.5 mg

Brand:
Cayman
CAS:
866022-28-8
Storage:
-20
UN-No:
Non-Hazardous - /

Bacterial type II fatty acid synthesis (FAS-II) is mediated by a series of enzymes, each of which may be targeted by potential antibiotics.{31077} Bischloroanthrabenzoxocinone (BABX) is an inhibitor of FAS-II, blocking fatty acid synthesis in S. aureus and E. coli with IC50 values of 11.4 and 35.3 µg/ml, respectively.{31076} It inhibits the growth of S. aureus and permeable E. coli strains with minimum inhibitory concentrations ranging from 0.2-0.4 µg/ml.{31076,31075} BABX also displays binding to liver X receptors (LXRs), inhibiting agonist binding in an LXRα-scintillation proximity assay (IC50 = 10 µM).{31075}  

 

Available on backorder

SKU: - Category:

Description

An inhibitor of FAS-II, blocking fatty acid synthesis in S. aureus and E. coli with IC50 values of 11.4 and 35.3 µg/ml, respectively; inhibits the growth of S. aureus and premeable E. coli strains with MICs ranging from 0.2-0.4 µg/ml


Formal name: (6R,16R)-10,12-dichloro-6,7,9,16-tetrahydro-11,13,15-trihydroxy-3-methoxy-1,6,9,9-tetramethyl-6,16-epoxy-14H-anthra[2,3-d][1]benzoxocin-14-one

Synonyms:  (―)-Bischloroanthrabenzoxocinone|BABX

Molecular weight: 543.4

CAS: 866022-28-8

Purity: ≥99%

Formulation: A light orange residue


Product Type|Biochemicals|Antibiotics||Product Type|Biochemicals|Natural Products||Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Endocrinology & Metabolism|Hormones & Receptors|FXRs & LXRs||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases